U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07898267) titled 'Gut Microbiota-Based Clinical Study of Akkermansia Supplementation for Overweight and Obesity' on Oct. 14.
Brief Summary: Overweight and obesity are common metabolic disorders associated with increased risks of diabetes, cardiovascular disease, and other health problems. The gut microbiota plays an important role in regulating metabolism, inflammation, and intestinal health. Akkermansia, a beneficial gut bacterium, has been associated with metabolic health and may have potential benefits for weight management.
This study aims to investigate the relationship between gut microbiota characteristics and overweight or obesity and to eva...